Combination therapy with lopinavir/ritonavir, ribavirin and interferon-α for Middle East respiratory syndrome.
Since the first report of Middle East respiratory syndrome (MERS) in 2012 in Saudi Arabia, no standard treatment guideline has been set despite the virulence of MERS-coronavirus (CoV) and the high case-fatality rate. The outbreak in South Korea in 2015 demonstrates that MERS outbreaks can occur outside of the Middle East. The combination of ribavirin and interferon-α has been the most widely used therapy for this infection. However, due to the varying results of treatment with these drugs, a new antiviral combination regimen is urgently needed. This is a case report of use of lopinavir/ritonavir-based combination antiviral therapy for a patient with MERS-CoV infection.
Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.
Uh Jin
UJ
Kim
Eun-Jeong
EJ
Won
Seung-Jung
SJ
Kee
Sook-In
SI
Jung
Hee-Chang
HC
Jang
D000998:Antiviral Agents / Q000008:administration & dosage*; D018352:Coronavirus Infections / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000821:virology; D004359:Drug Therapy, Combination; D006801:Humans; D016898:Interferon-alpha / Q000008:administration & dosage; D061466:Lopinavir / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D065207:Middle East Respiratory Syndrome Coronavirus / Q000187:drug effects / Q000235:genetics / Q000302:isolation & purification; D056910:Republic of Korea; D012254:Ribavirin / Q000008:administration & dosage; D019438:Ritonavir / Q000008:administration & dosage
D000998:Antiviral Agents; D016898:Interferon-alpha; D061466:Lopinavir; D012254:Ribavirin; D019438:Ritonavir